Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: persons (493), folks (1)

BRC EDI Prize_Guidelines

Description: NIHR BRC EDI Prize Call for Applications The NIHR Southampton Biomedical Research Centre is pleased to launch a new initiative designed to support projects
Url: /Media/Southampton-Clinical-Research/Downloads/BRC-EDI-Prize-Guidelines.docx

Belantamab Bortezomib Dexamethasone Weekly

Description: Chemotherapy Protocol BELANTAMAB MAFODOTIN – BORTEZOMIB - DEXAMETHASONE This protocol may require funding Regimen • Belantamab Mafodotin – Bortezomib - Dexamethasone Indication • 1 previous line of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Belantamab-Bortezomib-Dexamethasone-Weekly-Ver1.pdf

ARC 2 Theme Co-Lead Call for Expressions of Interest FINAL

Description: Call for Expressions of Interest: NIHR Applied Research Collaboration (ARC) Wessex Theme Co-Lead Designates, 2026-2031 The Universi
Url: /Media/Southampton-Clinical-Research/Downloads/ARC-2-Theme-Co-Lead-Call-for-Expressions-of-Interest-FINAL.pdf

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

Cyclophosphamide-Prednisolone-Rituximab- R-CP (21)

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB (R-CP) Regimen • Lymphoma – R-CP (21)-Cyclophosphamide-Prednisolone-Rituximab Indication • Ly
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Prednisolone-Rituximab-R-CP-21.pdf

Gastrointestinal (GI) late effects of cancer service - patient information

Description: This factsheet explains what our gastrointestinal (GI) late effects of cancer service is, what we offer and what happens next.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Gastrointestinal-GI-late-effects-of-cancer-service-3260-PIL.pdf

Carers support service - patient information

Description: This leaflet gives you useful information about our carers support service.
Url: /Media/UHS-website-2019/Patientinformation/Visitinghospital/Carers-support-service-3339-PIL.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

GvHDProphylaxisMethotrexateTReplete

Description: Chemotherapy Protocol SUPPORT REGIMEN–GvHD PROPHYLAXIS METHOREXATE – T Replete Allograft Graft versus Host Disease (GvHD) Prophylaxis This regimen will only be
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/GvHDProphylaxisMethotrexateTReplete.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

201 to 210 of 699

Previous … 19 20 21 22 23 … Next